Halozyme Therapeutics, Inc.
HALO
$71.48
$0.751.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 39.12% | 37.55% | 31.19% | 34.97% | 25.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.12% | 37.55% | 31.19% | 34.97% | 25.65% |
| Cost of Revenue | 38.40% | 30.11% | 5.00% | 1.43% | -3.34% |
| Gross Profit | 39.34% | 39.84% | 40.56% | 48.71% | 38.35% |
| SG&A Expenses | 29.31% | 25.31% | 15.11% | 16.52% | 9.94% |
| Depreciation & Amortization | 24.44% | 7.90% | 0.00% | -0.11% | -0.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.35% | 25.11% | 7.46% | 5.82% | 1.18% |
| Operating Income | 43.82% | 48.02% | 54.59% | 68.73% | 56.48% |
| Income Before Tax | -16.79% | -16.20% | 55.37% | 66.09% | 54.27% |
| Income Tax Expenses | 29.24% | 32.68% | 71.69% | 69.81% | 63.08% |
| Earnings from Continuing Operations | -28.13% | -28.64% | 51.73% | 65.22% | 52.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.13% | -28.64% | 51.73% | 65.22% | 52.25% |
| EBIT | 43.82% | 48.02% | 54.59% | 68.73% | 56.48% |
| EBITDA | 41.56% | 43.18% | 47.07% | 57.78% | 46.86% |
| EPS Basic | -24.20% | -25.45% | 59.02% | 71.10% | 57.10% |
| Normalized Basic EPS | 51.30% | 57.19% | 63.55% | 77.48% | 64.59% |
| EPS Diluted | -26.19% | -27.54% | 57.13% | 69.17% | 55.18% |
| Normalized Diluted EPS | 51.01% | 56.91% | 61.90% | 76.05% | 63.33% |
| Average Basic Shares Outstanding | -5.80% | -5.49% | -4.27% | -3.35% | -3.10% |
| Average Diluted Shares Outstanding | -5.43% | -5.11% | -3.31% | -2.54% | -2.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |